Clinical Trials
22
Active:1
Completed:5
Trial Phases
2 Phases
Phase 1:1
Phase 2:7
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 2
7 (87.5%)Phase 1
1 (12.5%)Intermediate Size Expanded Access Protocol Using Autologous HB-adMSCs for the Treatment of Parkinson's Disease
- Conditions
- Parkinson Disease
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Hope Biosciences Stem Cell Research Foundation
- Registration Number
- NCT06056427
HBCMD01- Expanded Access for the Treatment of Congenital Muscular Dystrophy.
- Conditions
- Congenital Muscular Dystrophy Due to Lamin A/C Mutation
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Hope Biosciences Stem Cell Research Foundation
- Registration Number
- NCT05154851
- Locations
- 🇺🇸
Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States
Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome
Phase 2
Completed
- Conditions
- Post COVID-19 Syndrome
- Interventions
- Other: Placebo
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Hope Biosciences Stem Cell Research Foundation
- Target Recruit Count
- 79
- Registration Number
- NCT05126563
- Locations
- 🇺🇸
Hope Biosciences Research Foundation, Sugar Land, Texas, United States
Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Hope Biosciences Stem Cell Research Foundation
- Target Recruit Count
- 24
- Registration Number
- NCT05116540
- Locations
- 🇺🇸
Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States
Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)
Phase 2
Active, not recruiting
- Conditions
- Parkinson Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Hope Biosciences Stem Cell Research Foundation
- Target Recruit Count
- 60
- Registration Number
- NCT04995081
- Locations
- 🇺🇸
Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found